The Unmet Need of Patients with Atrial Fibrillation: AVERROES and the Novel Oral Anticoagulants

1 Hart RG Pearce LA Aguilar MI . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–67.

2 Baker WL Cios DA Sander SD Coleman CI . Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. States. J Manag Care Pharm 2009; 15:244–52.

3 ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066–78.

4 Connolly SJ , Eikelboom J, for the AVERROES Steering Committee and Investigators et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806–17.

5 Singer DE Chang Y Fang . The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297–305.

6 Fang MC Go AS Chang Y . Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700–5.

7 Connolly SJ Ezekowitz MD Yusuf S . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–51.

8 Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: the ROCKET AF study. Abstract presented at the 2011 American Heart Association meeting, November, Chicago, IL, USA.

9 Sobieraj-Teague M O'Donnell M Eikelboom J . New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35:515–24.

10 Lopes BD Alexander JH Al-Khatib SM . Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159:331–9.